keyword
MENU ▼
Read by QxMD icon Read
search

Stelara

keyword
https://www.readbyqxmd.com/read/27765025/staphylococcus-aureus-bacteremia-with-iliac-artery-endarteritis-in-a-patient-receiving-ustekinumab
#1
Insa Joost, Johannes Steinfurt, Philipp T Meyer, Winfried V Kern, Siegbert Rieg
BACKGROUND: Ustekinumab (Stelara®), a human monoclonal antibody targeting the p40-subunit of interleukin (IL)-12 and IL-23, is indicated for moderate to severe plaque psoriasis and psoriatic arthritis. In large multicenter, prospective trials assessing efficacy and safety of ustekinumab increased rates of severe infections have not been observed so far. CASE PRESENTATION: Here, we report the case of a 64-year old woman presenting with chills, pain and swelling of her right foot with dark maculae at the sole, and elevated inflammatory markers...
October 20, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/25624139/-ustekinumab-induced-eosinophilic-pneumonia-during-the-course-of-ustekinumab-therapy-for-plaque-psoriasis
#2
M Amy de la Bretèque, C Appere-De Vecchi, C Zeboulon, I Zaien, M-L Sigal, E Mahé
BACKGROUND: Ustekinumab (Stelara(®)) is efficacious in severe cutaneous psoriasis. Numerous adverse effects have been reported but treatment withdrawal is rarely required. The present case concerns eosinophilic pneumonia treated with ustekinumab. PATIENT AND METHODS: A 71-year-old male patient presented severe plaque psoriasis with an indication for biotherapy. Pre-treatment investigations showed a highly positive interferon gamma test without any anomalies in the CT chest scan...
March 2015: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/25176428/patent-watch-stelara-safe-after-il-12-antibody-dispute
#3
REVIEW
Charlotte Harrison
No abstract text is available yet for this article.
September 2014: Nature Reviews. Drug Discovery
https://www.readbyqxmd.com/read/24919864/ustekinumab-a-review-of-its-use-in-psoriatic-arthritis
#4
REVIEW
Kate McKeage
Ustekinumab (Stelara(®)) is a human monoclonal antibody that binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, blocking signalling of their cognate receptors. It is established in the treatment of moderate-to-severe plaque psoriasis, but recently received approval in adults with active psoriatic arthritis. Tumour necrosis factor (TNF) inhibitors remain first-line biological agents for the treatment of psoriatic arthritis, but alternative agents are needed. This article summarises the pharmacology of ustekinumab and reviews its use in phase 3 trials in psoriatic arthritis...
June 2014: Drugs
https://www.readbyqxmd.com/read/24662976/certolizumab-pegol-cimzia-and-ustekinumab-stelara-for-psoriatic-arthritis
#5
(no author information available yet)
No abstract text is available yet for this article.
February 3, 2014: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/24391391/pharmaceutical-approval-update
#6
Marvin M Goldenberg
Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma.
November 2013: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/23745965/long-term-safety-of-ustekinumab-for-psoriasis
#7
REVIEW
Neal Kumar, Kirti Narang, Brienne D Cressey, Alice B Gottlieb
INTRODUCTION: The biologic, Ustekinumab (Stelara®, Centocor, Inc., Malvern, PA, USA), is a fully human monoclonal antibody with a high affinity for the shared p40 subunit of interleukins 12 and 23 (IL-12 and IL-23). Approved for use in treating moderate-to-severe psoriasis in 2009, there has been considerable interest in the long-term safety of ustekinumab. AREAS COVERED: This review discusses the use of ustekinumab in the treatment of psoriasis and its potential to be an effective and well-tolerated therapy...
September 2013: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/23349185/interleukins-12-and-23-do-not-alter-expression-or-activity-of-multiple-cytochrome-p450-enzymes-in-cryopreserved-human-hepatocytes
#8
Shannon Dallas, Souvik Chattopadhyay, Carlo Sensenhauser, Ameesha Batheja, Monica Singer, Jose Silva
Psoriasis is a T-cell-mediated autoimmune disease involving the skin. Two cytokines, interleukin-12 (IL-12) and IL-23 have been shown to play a pivotal role in the pathogenesis of the disease. Ustekinumab (Stelara) is a therapeutic monoclonal antibody (mAb) targeted against the p40 shared subunit of IL-12 and IL-23. Recently the ability of therapeutic proteins (TP) including mAbs that target either cytokines directly (e.g., Pegasys; peginterferon α-2a) or their respective cell surface receptors [e.g., tocilizumab (Actemra); anti IL-6R] to desuppress cytochrome P450 (P450) enzymes in vitro and in the clinic, has been demonstrated...
April 2013: Drug Metabolism and Disposition: the Biological Fate of Chemicals
https://www.readbyqxmd.com/read/22270196/ustekinumab-a-review-in-the-treatment-of-plaque-psoriasis-and-psoriatic-arthritis
#9
REVIEW
Daniel Zaghi, Gerald G Krueger, Kristina Callis Duffin
Psoriasis is a complex, multigenic immune/inflammatory-mediated disorder that variably affects the skin, nails, and joints. In September 2009, ustekinumab (Stelara®), a monoclonal antibody that targets interleukin 12 (IL-12) and 23 (IL-23), was approved in the United States for treatment of moderate-to-severe plaque psoriasis. The drug's mechanism of action is derived from extensive immunologic and genomic research identifying IL-12 and IL-23 of the Th1 and Th17 inflammatory pathways, respectively, as key mediators of psoriasis...
February 2012: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/22201419/spotlight-on-ustekinumab-in-moderate-to-severe-plaque-psoriasis
#10
Jamie D Croxtall
Ustekinumab (Stelara™) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23. It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the EU, it is indicated for those who failed to respond to, have a contraindication to, or are intolerant of other systemic therapies or phototherapy. In well designed, randomized clinical trials, regimens of subcutaneous ustekinumab 45 or 90 mg provided a rapid and durable improvement in Psoriasis Area and Severity Index scores for patients with moderate to severe plaque psoriasis...
April 1, 2012: American Journal of Clinical Dermatology
https://www.readbyqxmd.com/read/22137636/-patient-education-information-letter-on-treatment-of-psoriasis-with-ustekinumab-stelara
#11
(no author information available yet)
No abstract text is available yet for this article.
December 2011: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/21902296/ustekinumab-a-review-of-its-use-in-the-management-of-moderate-to-severe-plaque-psoriasis
#12
REVIEW
Jamie D Croxtall
Ustekinumab (Stelara™) is a human monoclonal antibody that binds to the p40 subunit common to both interleukin (IL)-12 and IL-23. It is indicated in the US for use in adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. In the EU, it is indicated for those who failed to respond to, have a contraindication to or are intolerant of other systemic therapies or phototherapy. This article reviews the efficacy and tolerability of ustekinumab in patients with moderate to severe plaque psoriasis, as well as summarizing its pharmacological properties...
September 10, 2011: Drugs
https://www.readbyqxmd.com/read/20430307/anti-p40-antibodies-ustekinumab-and-briakinumab-blockade-of-interleukin-12-and-interleukin-23-in-the-treatment-of-psoriasis
#13
REVIEW
Mona Gandhi, Eihab Alwawi, Kenneth B Gordon
The choice of therapeutic agents for patients with moderate-to-severe psoriasis has expanded significantly in the past decade. With new understanding of the immunologic basis of psoriasis, multiple new potential targets for therapy have been identified. It is likely that a series of new medications to focus on the newly identified pathways is on the horizon. The first pathway targeted by new medications focuses on the p40 subunit that is shared by interleukin (IL)-12 and IL-23. Two human anti-p40 antibodies have been used therapeutically in psoriasis to date, ustekinumab (CNTO-1275, Stelara, Centocor, Horsham, PA) and briakinumab (ABT-874, Abbott, Abbott Park, IL)...
March 2010: Seminars in Cutaneous Medicine and Surgery
https://www.readbyqxmd.com/read/20208473/ustekinumab-stelara-for-psoriasis
#14
(no author information available yet)
No abstract text is available yet for this article.
January 25, 2010: Medical Letter on Drugs and Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"